Yi-Kun Kang1, Yi-Ran Si1, Guang-Yu An2, Peng Yuan1. 1. Department of VIP Medical Services, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Abstract
BACKGROUND: Our study aimed to compare the efficacy and safety of anthracycline plus taxane (AT)-based neoadjuvant chemotherapy (NAC) with or without cyclophosphamide in the treatment of breast cancer. METHODS: We searched PubMed, Embase, Web of Science and the Cochrane Library for randomized controlled studies comparing the efficacy and safety of AT-based NAC with or without cyclophosphamide in breast cancer patients. RESULTS: Four eligible studies with 2,302 individuals were ultimately included in the quantitative analysis. After applying the AT-based NAC regimen, the overall rates of pathologic complete response (pCR) and breast conserving surgery in all included subjects were 26.5% and 70.6%, respectively. The rates of pCR [risk ratio (RR): 1.35; 95% CI: 0.75, 2.45; P=0.32], breast-conserving surgery (RR: 1.07; 95% CI: 0.97, 1.19; P=0.17) and clinical response (RR: 1.08; 95% CI: 0.97, 1.19; P=0.15) in patients in the cyclophosphamide group were similar to those in the control group. However, participants in the cyclophosphamide group had a lower no clinical response rate than those in the control group (RR: 0.72; 95% CI: 0.60, 0.87; P<0.001). Subjects in the cyclophosphamide group had significantly lower rates of infection (RR: 0.57; 95% CI: 0.41, 0.79; P<0.001) and diarrhea (RR: 0.46; 95% CI: 0.30, 0.68; P<0.001) and higher rates of thrombocytopenia (RR: 3.38; 95% CI: 1.96, 5.84; P<0.001), sensory/motor neuropathy (RR: 1.57; 95% CI: 1.03, 2.39; P=0.03) and nausea/vomiting (RR: 1.51; 95% CI: 1.11, 2.06; P=0.009) than those in the control group. CONCLUSIONS: The AT-based NAC regimen with or without cyclophosphamide had similar clinical outcomes in breast cancer patients. The addition of cyclophosphamide might increase the risks of thrombocytopenia, sensory/motor neuropathy and nausea/vomiting. 2021 Gland Surgery. All rights reserved.
BACKGROUND: Our study aimed to compare the efficacy and safety of anthracycline plus taxane (AT)-based neoadjuvant chemotherapy (NAC) with or without cyclophosphamide in the treatment of breast cancer. METHODS: We searched PubMed, Embase, Web of Science and the Cochrane Library for randomized controlled studies comparing the efficacy and safety of AT-based NAC with or without cyclophosphamide in breast cancer patients. RESULTS: Four eligible studies with 2,302 individuals were ultimately included in the quantitative analysis. After applying the AT-based NAC regimen, the overall rates of pathologic complete response (pCR) and breast conserving surgery in all included subjects were 26.5% and 70.6%, respectively. The rates of pCR [risk ratio (RR): 1.35; 95% CI: 0.75, 2.45; P=0.32], breast-conserving surgery (RR: 1.07; 95% CI: 0.97, 1.19; P=0.17) and clinical response (RR: 1.08; 95% CI: 0.97, 1.19; P=0.15) in patients in the cyclophosphamide group were similar to those in the control group. However, participants in the cyclophosphamide group had a lower no clinical response rate than those in the control group (RR: 0.72; 95% CI: 0.60, 0.87; P<0.001). Subjects in the cyclophosphamide group had significantly lower rates of infection (RR: 0.57; 95% CI: 0.41, 0.79; P<0.001) and diarrhea (RR: 0.46; 95% CI: 0.30, 0.68; P<0.001) and higher rates of thrombocytopenia (RR: 3.38; 95% CI: 1.96, 5.84; P<0.001), sensory/motor neuropathy (RR: 1.57; 95% CI: 1.03, 2.39; P=0.03) and nausea/vomiting (RR: 1.51; 95% CI: 1.11, 2.06; P=0.009) than those in the control group. CONCLUSIONS: The AT-based NAC regimen with or without cyclophosphamide had similar clinical outcomes in breast cancer patients. The addition of cyclophosphamide might increase the risks of thrombocytopenia, sensory/motor neuropathy and nausea/vomiting. 2021 Gland Surgery. All rights reserved.
Entities:
Keywords:
Neoadjuvant chemotherapy (NAC); anthracycline; breast cancer; cyclophosphamide; taxane
Authors: Rafael Caparica; Marco Bruzzone; Francesca Poggio; Marcello Ceppi; Evandro de Azambuja; Matteo Lambertini Journal: Breast Cancer Res Treat Date: 2018-11-21 Impact factor: 4.872
Authors: Lindsey A Torre; Farhad Islami; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-21 Impact factor: 4.254
Authors: Woo Sung Hong; Ja Young Jeon; Seok Yun Kang; Yong Sik Jung; Ji Young Kim; Mi Sun Ahn; Doo Kyoung Kang; Tae Hee Kim; Hyun Ee Yim; Young-Sil An; Rae Woong Park; Ku Sang Kim Journal: J Korean Surg Soc Date: 2013-06-26
Authors: Gun Min Kim; Joo Hoon Kim; Ji Heung Kim; Young Up Cho; Seung Il Kim; Seho Park; Hyung Seok Park; Ji Ye Kim; Joohyuk Sohn Journal: Cancer Res Treat Date: 2018-09-19 Impact factor: 4.679
Authors: Sibylle Loibl; Gunter von Minckwitz; Nadia Harbeck; Wolfgang Janni; Dirk Elling; Manfred Kaufmann; Holm Eggemann; Valentina Nekljudova; Harald Sommer; Marion Kiechle; Sherko Kümmel Journal: Breast Cancer Res Date: 2008-09-16 Impact factor: 6.466
Authors: Sri Susilowati; Hermawan Istiadi; Suhartono Suhartono; Yan Wisnu Prajoko; Ignatius Riwanto; Neni Susilaningsih; Catharina Suharti Journal: Asian Pac J Cancer Prev Date: 2022-03-01